TRK inhibitors achieve these effects by binding to the ATP binding site of NTRK fusion proteins, preventing the phosphorylation of downstream signalling molecules and blocking the transmission of growth signals within cancer cells (Table 1) [16]. The gene discussed is TPM3; the disease is cancer.